<DOC>
	<DOCNO>NCT00156208</DOCNO>
	<brief_summary>The objective study determine long-term safety asoprisnil woman symptomatic uterine fibroid complete 6 month Study C02-037 .</brief_summary>
	<brief_title>Safety Treatment Uterine Fibroids With Asoprisnil</brief_title>
	<detailed_description>No medical therapy currently available long-term treatment abnormal uterine bleeding associate uterine fibroid woman many woman must resort surgery relief . The objective study determine long-term safety asoprisnil 10 25 mg administer daily 18 month subject symptomatic uterine leiomyomata complete 6 month Study C02-037 . The safety endpoint study base assessment endometrium , ovarian cyst , lipid profile , adverse event clinical laboratory evaluation . Some subject receive asoprisnil develop endometrial change . As result , dose prematurely discontinue subject . To ensure safety , subject remain study undergo schedule study procedure . In subject , endometrial change reverse asoprisnil discontinuation .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<criteria>Women complete 6 month treatment study C02037 7day interruption treatment Otherwise good health Premenopausal base Estrogen Follicle Stimulating Hormone level Agrees doublebarrier method contraception Adequate endometrial biopsy significant histological disorder Any abnormal lab procedure result ( ) studydoctor considers important History bloodclotting disorder Any prior surgical and/or invasive procedure ( ) uterine fibroid result either cure make symptom go away Significant gynecological disorder , endometrial polyp</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Symptomatic Uterine Fibroids</keyword>
	<keyword>Excessive Uterine Bleeding</keyword>
	<keyword>Uterine Hemorrhage</keyword>
	<keyword>asoprisnil</keyword>
</DOC>